@article{20b9636c2b0142298ce0103276f58590,
title = "The leukodystrophy mutation Polr3b R103H causes homozygote mouse embryonic lethality and impairs RNA polymerase III biogenesis",
abstract = "Recessive mutations in the ubiquitously expressed POLR3A and POLR3B genes are the most common cause of POLR3-related hypomyelinating leukodystrophy (POLR3-HLD), a rare childhood-onset disorder characterized by deficient cerebral myelin formation and cerebellar atrophy. POLR3A and POLR3B encode the two catalytic subunits of RNA Polymerase III (Pol III), which synthesizes numerous small non-coding RNAs. We recently reported that mice homozygous for the Polr3a mutation c.2015G > A (p.Gly672Glu) have no neurological abnormalities and thus do not recapitulate the human POLR3-HLD phenotype. To determine if other POLR3-HLD mutations can cause a leukodystrophy phenotype in mouse, we characterized mice carrying the Polr3b mutation c.308G > A (p.Arg103His). Surprisingly, homozygosity for this mutation was embryonically lethal with only wild-type and heterozygous animals detected at embryonic day 9.5. Using proteomics in a human cell line, we found that the POLR3B R103H mutation severely impairs assembly of the Pol III complex. We next generated Polr3a G672E/G672E /Polr3b +/R103H double mutant mice but observed that this additional mutation was insufficient to elicit a neurological or transcriptional phenotype. Taken together with our previous study on Polr3a G672E mice, our results indicate that missense mutations in Polr3a and Polr3b can variably impair mouse development and Pol III function. Developing a proper model of POLR3-HLD is crucial to gain insights into the pathophysiological mechanisms involved in this devastating neurodegenerative disease.",
keywords = "Leukodystrophy, Mouse model, Myelination, POLR3A, POLR3B, RNA polymerase III",
author = "Karine Choquet and Maxime Pinard and Sharon Yang and Moir, {Robyn D.} and Christian Poitras and Dicaire, {Marie Jos{\'e}e} and Nicolas Sgarioto and Roxanne Larivi{\`e}re and Kleinman, {Claudia L.} and Willis, {Ian M.} and Gauthier, {Marie Soleil} and Benoit Coulombe and Bernard Brais",
note = "Funding Information: All experiments were carried out according to good practice of handling laboratory animals consistent with the Canadian Council on Animal Care and approved by the University Animal Care Committee. The mouse line C57BL/6 N-Polr3b < em4Tcp>(Polr3b+/R103H) was made as part of the NorCOMM2 project funded by the Care4Rare Canada Consortium, Genome Canada and the Ontario Genomics Institute (OGI-051) at the Toronto Centre for Phenogenomics. It was obtained from the Canadian Mouse Mutant Repository. Briefly, the mutant allele was created using CRISPR-Cas9, by injecting the Cas9 protein, single guide RNA (5′-TCATGTCCCTCAGACGG-CAC-3′) and single-strand oligonucleotide repair template (5′-gtgcactgtattcacagtgggattgctggagggcaggggtcgctcgctcactgt-gattctgcttcagTGCCATCTGAGGGACATGACGTACTCC GCCCCAATCACAGTGGACATTGAGTATACCCGAG GCAGCCAGAGGA-3′) including the c.308G > A mutation and the intronic mutation c.304-4C > T to prevent reediting of the properly mutated genomic DNA. For determination of the lethality of Polr3bR103H/R103H mice, heterozygous Polr3b+/R103Hmice were interbred and gestating females were sacrificed at E9.5 to extract embryos for geno-typing. The generation of Polr3aG672E/G672Emice was previously described [6]. For the production of DM mice, Polr3aG672E/G672E and Polr3b+/R103H were bred, resulting in 50% Polr3a+/G672E/Polr3b+/R103H and 50% Polr3a+/G672E/ Polr3b+/+ mice. Polr3a+/G672E/Polr3b+/R103H males and females were subsequently bred together to generate Polr3a-G672E/G672E/Polr3b+/R103H DM mice. Funding Information: This project was supported by grants from the Fondation Leuco Dystrophie, the European Leukodystrophy Association and the Canadian Institutes of Health Research (CIHR) (MOP #126141). The mouse line C57BL/6 N-Polr3b< em4Tcp> was made as part of the NorCOMM2 project, funded by the Care4Rare Canada Consortium, Genome Canada and the Ontario Genomics Institute (OGI-051) at the Toronto Centre for Phenogenomics. KC received doctoral awards from the Fonds de Recherche en Sant{\'e} – Qu{\'e}bec (FRQS), the Fondation Grand D{\'e}fi Pierre Lavoie and the Jewish General Hospital National Bank Molecular Pathology Scholarship. CLK receives a salary award from the FRQS. Publisher Copyright: {\textcopyright} 2019 The Author(s).",
year = "2019",
month = jun,
day = "20",
doi = "10.1186/s13041-019-0479-7",
language = "English (US)",
volume = "12",
journal = "Molecular Brain",
issn = "1756-6606",
publisher = "BioMed Central",
number = "1",
}